The short answer
Usually not hormone therapy for the whole body. The Menopause Society says it is generally not advised after breast cancer, after a trial found more recurrences on it. Vaginal estrogen may be considered with your oncologist when non-hormonal treatments have not helped.
Who this answer is for
This applies to
- Women who have had breast cancer, or are being treated for it, and now have hot flashes, night sweats, vaginal dryness or pain with sex
- Women on tamoxifen or an aromatase inhibitor whose menopause symptoms started or worsened with treatment
This does not apply to
- Women with a family history of breast cancer but no diagnosis of their own: that is a different conversation with your physician
- Anyone with a new breast lump or other breast change, which needs an in-person exam first
Two trials, two different answers
Only two randomized trials have tested hormone therapy in breast cancer survivors, and both were in Sweden and Norway. HABITS was stopped early in 2003: after a median of 2.1 years, 26 women on hormone therapy and 7 in the comparison group had a new breast cancer event [1]. The Stockholm trial, which deliberately kept progestogen exposure low, saw no increase at 4.1 years [2].
| HABITS | Stockholm | |
|---|---|---|
| Women in the final analysis | 442, split 221 and 221 [3] | Women with a history of breast cancer, randomized [2] |
| Follow-up | Median 4 years [3] | Median 4.1 years, later 10.8 years [2] [4] |
| New breast cancer events | 39 on hormone therapy vs 17 without; hazard ratio 2.4 [3] | Relative hazard 0.82 at 4.1 years [2]; 1.3 at 10.8 years, not statistically significant [4] |
| 5-year cumulative incidence | 22.2% vs 8.0% [3] | Not reported in these terms |
| Other breast | More cancers in the other breast at 10.8 years (hazard ratio 3.6) [4] |
The two trials disagree more than chance would explain [2]. Most women in HABITS took estradiol with norethisterone, a progestin [3]. What the trials agree on is that the risk is real enough to take seriously, and that is why the guidance is cautious.
What the guidance says
- The Menopause Society: systemic hormone therapy is generally not advised for breast cancer survivors, though it may be considered for severe hot flashes that have not responded to non-hormonal options, decided together with the oncologist [4].
- The labels: current or past breast cancer is on the list of reasons not to use estradiol, including on the gel label revised in February 2026 [5].
- NICE, for vaginal symptoms: offer non-hormonal moisturisers or lubricants first; consider vaginal estrogen if symptoms continue; for women on an aromatase inhibitor, work with a breast cancer specialist [6].
Vaginal estrogen is a separate question
Low-dose vaginal estrogen puts far less estrogen into the blood than a patch or pill. In a Danish cohort of 8,461 women treated for estrogen receptor-positive early breast cancer, vaginal estrogen was not linked to recurrence overall (relative risk 1.08), but it was in women taking an aromatase inhibitor (1.39), without a rise in deaths [7]. In 49,237 women in Scotland and Wales, vaginal estrogen was not linked to higher breast cancer mortality [8]. Both studies observed women rather than randomizing them. The Menopause Society’s vaginal health statement says care for women with breast cancer should follow their oncologist [9]. More on the forms is on the vaginal estrogen page.
If hormones are off the table
Hot flashes after breast cancer can still be treated. A physician may offer a non-hormonal medicine, such as escitalopram, which is FDA-approved for depression and anxiety and used off-label for hot flashes, and will check it against your cancer medicines. For vaginal dryness, moisturisers and lubricants come first [6]. The menopause care page lists every option a VevaMD physician may consider.
If you have no history of breast cancer and are weighing estradiol, the estradiol page has the absolute numbers from the Women’s Health Initiative. If migraine is your other concern, see HRT with migraine with aura; if low desire is, see does testosterone work for women?
VevaMD is a technology company, not a medical provider. Educational content only, not medical advice. A US-licensed physician decides whether any treatment fits you, and a prescription is not guaranteed.
Sources
- Holmberg L, Anderson H; HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363(9407):453-455. Checked October 23, 2026.
- von Schoultz E, Rutqvist LE; Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst. 2005;97(7):533-535. Checked October 23, 2026.
- Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100(7):475-482. Checked October 23, 2026.
- The North American Menopause Society. The 2022 hormone therapy position statement. Menopause. 2022;29(7):767-794. Checked October 23, 2026.
- Divigel® (estradiol gel) prescribing information, revised February 2026. DailyMed. Checked October 23, 2026.
- National Institute for Health and Care Excellence (NICE). Menopause: identification and management (NG23). Recommendations, updated April 2026. Checked October 23, 2026.
- Cold S, Cold F, Jensen MB, et al. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 2022;114(10):1347-1354. Checked October 23, 2026.
- McVicker L, Labeit AM, Coupland CAC, et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol. 2024;10(1):103-108. Checked October 23, 2026.
- The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. Checked October 23, 2026.